Last reviewed · How we verify
BGB-A445
BGB-A445 is a Bcl-2 inhibitor that promotes apoptosis in cancer cells by blocking anti-apoptotic proteins.
BGB-A445 is a Bcl-2 inhibitor that promotes apoptosis in cancer cells by blocking anti-apoptotic proteins. Used for Chronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL), Follicular lymphoma.
At a glance
| Generic name | BGB-A445 |
|---|---|
| Also known as | Gimistotug |
| Sponsor | BeiGene |
| Drug class | Bcl-2 inhibitor |
| Target | Bcl-2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
BGB-A445 selectively inhibits B-cell lymphoma 2 (Bcl-2) family proteins, which are frequently overexpressed in hematologic malignancies and prevent programmed cell death. By blocking these anti-apoptotic signals, the drug restores the ability of cancer cells to undergo apoptosis. This mechanism is particularly effective in cancers dependent on Bcl-2 for survival.
Approved indications
- Chronic lymphocytic leukemia (CLL)
- Small lymphocytic lymphoma (SLL)
- Follicular lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Tumor lysis syndrome
- Infection
Key clinical trials
- Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (PHASE3)
- A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors. (PHASE1, PHASE2)
- A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer (PHASE2)
- A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer (PHASE2)
- Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BGB-A445 CI brief — competitive landscape report
- BGB-A445 updates RSS · CI watch RSS
- BeiGene portfolio CI